Abstract:Duchenne muscular dystrophy (DMD) results from mutations in the largest known gene, dystrophin. Gene therapy for DMD will require methods to systemically deliver a therapeutic dystrophin gene to widely distributed muscles. Recent observations indicating that vascularly transplanted adult stem cells can home and become muscle cells in an appropriate micro-environment has suggested one possible method for delivering genes to muscle. A smaller, easily traceable, and functional dystrophin would facilitate experiments aimed at improving ex vivo cell-based strategies. We previously found that large portions of the dystrophin central rod domain (Hinge 2 to Repeat 19) and the C-terminal domain (encoded on exons 71 to Exon 78) are not essential for the full function of dystrophin, as assayed by the ability to prevent and partially reverse morphological and fucnional abnormalities in mdx mouse skeletal muscles. Here, we engineered a 5.7-kb MiniDys-eGFP fusion gene by replacing the C-terminal domain of mini-dystrophin (DH2-R19) with an enhanced green fluorescence gene coding sequence and by trimming down the size of 5' and 3' UTR of dystrophin. This fusion gene can be inserted into lentiviral vectors and efficiently delivered into a variety of cell types in vitro. This MiniDys-eGFP fusion protein was found to fully prevent dystrophy of multiple skeletal muscles in transgenic mdx mice carrying the fusion gene under the control of the human a-skeletal actin (HSA) gene promoter. This green fusion protein was easily observed by fluorescence microscopy on the sarcolemma of skeletal muscle fibers of the transgenic mdx mice. Furthermore, donor-derived GFP-positive myofibers were detected in mdx recipient muscles transplanted with either whole bone marrow cells or primary myoblasts isolated from the MiniDys-eGFP transgenic mice. These data indicate that the smaller, easily traceable, and functional MiniDys-eGFP will be useful for developing ex vivo cell-based gene therapies for DMD.

Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models

Research Progress on Disease Models and Gene Therapy of Duchenne Muscular Dystrophy

242. A Novel MiniDys-eGFP Fusion Gene for Developing Cell-Based Therapies of Duchenne Muscular Dystrophy

Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy

Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy

Hydroxyapatite nanoparticle mediated delivery of full length dystrophin gene as a potential therapeutic for the treatment of Duchenne muscular dystrophy

Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse model of Duchenne Muscular Dystrophy

Long-term Effect of Human Mini-Dystrophin in Transgenic Mdx Mice Improves Muscle Physiological Function.

Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy

Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy

Molecular Pathogenesis of Genetic and Inherited Diseases Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein

Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model

Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids

A Non-Viral Vector for Potential DMD Gene Therapy Study by Targeting a Minidystrophin-Gfp Fusion Gene into the Hrdna Locus.

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

37. Long-Term Expression of Mini-Human Dystrophin in Transgenic mdx Mice Improves Dystrophic Muscle Functions

Cardiac-Specific Expression of ΔH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy

Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments

Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy